In multiple phase II trials (NCT01373151, NCT00867516) with moderate or severe RA or inadequate response to MTX, CLZ had a long half-life, was well tolerated, had rapid improvements in patient mobility and HRQoL, and changes in laboratory indicators (eg, increased aminotransferases, slight injection responses, neutrophil reductions) were within the range of IL-6 inhibitors. The gene discussed is IL6; the disease is rheumatoid arthritis.